[go: up one dir, main page]

GB202306663D0 - Combination therapy - Google Patents

Combination therapy

Info

Publication number
GB202306663D0
GB202306663D0 GBGB2306663.2A GB202306663A GB202306663D0 GB 202306663 D0 GB202306663 D0 GB 202306663D0 GB 202306663 A GB202306663 A GB 202306663A GB 202306663 D0 GB202306663 D0 GB 202306663D0
Authority
GB
United Kingdom
Prior art keywords
combination therapy
therapy
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2306663.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Union Therapeutics AS
Original Assignee
Union Therapeutics AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Union Therapeutics AS filed Critical Union Therapeutics AS
Priority to GBGB2306663.2A priority Critical patent/GB202306663D0/en
Publication of GB202306663D0 publication Critical patent/GB202306663D0/en
Priority to PCT/EP2024/062354 priority patent/WO2024231312A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2306663.2A 2023-05-05 2023-05-05 Combination therapy Ceased GB202306663D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2306663.2A GB202306663D0 (en) 2023-05-05 2023-05-05 Combination therapy
PCT/EP2024/062354 WO2024231312A2 (en) 2023-05-05 2024-05-03 Combination therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2306663.2A GB202306663D0 (en) 2023-05-05 2023-05-05 Combination therapy

Publications (1)

Publication Number Publication Date
GB202306663D0 true GB202306663D0 (en) 2023-06-21

Family

ID=86763461

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2306663.2A Ceased GB202306663D0 (en) 2023-05-05 2023-05-05 Combination therapy

Country Status (2)

Country Link
GB (1) GB202306663D0 (en)
WO (1) WO2024231312A2 (en)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5229318B2 (en) 1972-03-30 1977-08-01
CN1046939C (en) 1993-07-02 1999-12-01 比克·古尔顿·劳姆贝尔格化学公司 Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
CN100415743C (en) 1999-03-31 2008-09-03 韦尔纳利斯有限公司 Pyrimido [6, 1-a ] isoquinolin-4-one derivatives
CA2427814C (en) 2000-11-07 2009-06-02 Merck & Co., Inc. A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
BRPI0519030A2 (en) 2004-12-13 2008-12-23 Celgene Corp methods of treating, preventing, or controlling inflammation of the airways and of a disease or disorder of the airways or lungs, and pharmaceutical composition
PT3424932T (en) 2005-02-16 2021-05-19 Anacor Pharmaceuticals Inc Boronophthalides for therapeutic use
EP1874308A1 (en) * 2005-03-08 2008-01-09 Nycomed GmbH Roflumilast for the treatment of diabetes mellitus
AR057891A1 (en) 2005-11-15 2007-12-26 Otsuka Pharma Co Ltd OXAZOL COMPOUNDS AND PHARMACEUTICAL COMPOSITION
RU2508113C2 (en) 2006-02-16 2014-02-27 Анакор Фармасьютикалз, Инк. Boron-based small molecules as anti-inflammatory drugs
BRPI0716134A2 (en) * 2006-09-07 2013-09-17 Nycomed Gmbh combination treatment for diabetes mellitus
JP4986927B2 (en) 2007-05-14 2012-07-25 大塚製薬株式会社 Medicine
PL2276483T3 (en) 2008-03-27 2014-09-30 Celgene Corp Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
EP2156835A1 (en) 2008-08-19 2010-02-24 Sanofi-Aventis New therapeutic use of drotaverine
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
CN107964016B (en) 2009-05-14 2021-10-01 天津合美医药科技有限公司 Thiophene derivatives
PT2585469T (en) 2010-06-24 2016-08-29 Leo Pharma As Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors
CN106377503A (en) 2010-08-03 2017-02-08 奇斯药制品公司 Pharmaceutical formulations comprising phosphodiesterase inhibitor
BR112013029621A2 (en) 2011-05-20 2016-12-13 Chinoin Private Co Ltd pharmaceutical composition comprising drotaverine
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
BR112015004023A2 (en) 2012-08-30 2017-07-04 Otsuka Pharma Co Ltd compound, and method for producing a compound
HRP20230162T1 (en) 2012-10-25 2023-04-14 Tetra Discovery Partners Llc Heteroaryl inhibitors of pde4
WO2014124860A1 (en) * 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
RU2561489C2 (en) 2013-05-14 2015-08-27 Вадим Петрович Бахарев Drotaverine synthesis method
PT3157930T (en) 2014-06-23 2018-12-24 Leo Pharma As Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
ES2961237T3 (en) 2015-12-18 2024-03-11 Union Therapeutics As Methods for the preparation of 1,3-benzodioxol heterocyclic compounds
TWI726027B (en) 2015-12-28 2021-05-01 日商大塚製藥股份有限公司 Ointment
US10570147B2 (en) 2017-06-13 2020-02-25 Biotheryx, Inc. Bicyclic compounds and methods of use
WO2018234299A1 (en) 2017-06-20 2018-12-27 Leo Pharma A/S PROCESSES FOR THE PREPARATION OF 1,3-BENZODIOXOLE HETEROCYCLIC COMPOUNDS
FI3774745T3 (en) 2018-04-04 2024-06-19 Otsuka Pharma Co Ltd Oxazole compound crystal
BR112021005870B1 (en) 2018-10-05 2024-01-09 Pfizer Inc PDE4 INHIBITORS CONTAINING BORON
EP4282414A3 (en) 2019-01-15 2024-02-21 UNION therapeutics A/S Modified release tablet formulations containing phosphodiesterase inhibitors
JP7767264B2 (en) 2019-09-02 2025-11-11 ノヴォ ノルディスク アー／エス Process for producing tablets containing GLP-1 peptides
JP7051968B2 (en) 2019-10-09 2022-04-11 大塚製薬株式会社 Oxazole compound crystals

Also Published As

Publication number Publication date
WO2024231312A3 (en) 2024-12-19
WO2024231312A2 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
CA221425S (en) Therapy eye-mask
IL319599A (en) Combination therapy
IL304223A (en) Combination therapy
GB202004189D0 (en) Combination therapy
IL318268A (en) Combination therapy
GB202002639D0 (en) Therapy
GB202111288D0 (en) Combination therapy
GB202104037D0 (en) Combination therapy
IL325619A (en) Combination therapy
GB202318311D0 (en) Combination therapy
GB202317996D0 (en) Combination therapy
GB202316168D0 (en) Combination therapy
GB202315149D0 (en) Combination therapy
GB202314243D0 (en) Combination therapy
GB202314157D0 (en) Combination therapy
GB202306663D0 (en) Combination therapy
GB202218974D0 (en) Combination therapy
GB202207792D0 (en) Combination therapy
GB202205317D0 (en) Combination therapy
GB202201346D0 (en) Combination therapy
GB202315877D0 (en) Therapy
GB202306826D0 (en) Therapy
GB202306835D0 (en) Therapy
GB202306833D0 (en) Therapy
GB202303026D0 (en) Therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)